Kenvue Inc. (NYSE: KVUE) has seen a dynamic shift in its stock ownership, with various asset management firms and investment advisors such as Envestnet Asset Management Inc. and Rafferty Asset Management LLC acquiring shares, while others including Belpointe Asset Management LLC and Stifel Financial Corp offloaded their stake. Meanwhile, Johnson & Johnson plans to sell its remaining stake in Kenvue. The biotech company's Q1 2024 earnings call transcript is available, indicating moderate financial performances; however, some hold the view that earnings figures might not reflect Kenvue's actual potential. The firm has recently been rated 'Hold' by analysts and received average brokerages’ ratings. The company's recent layoffs and the announcement of a secondary stock offering have created an unstable climate around the stock. Interestingly, Kenvue's alignment with analyst EPS projections amidst strategic changes indicates market resilience. The company seems to have 'worst-in-class' growth, indicated by its share slides, but its strong fundamentals suggest that the market's bearish outlook could be flawed.
Kenvue KVUE News Analytics from Thu, 19 Oct 2023 07:00:00 GMT to Sun, 09 Jun 2024 17:04:38 GMT -
Rating 0
- Innovation -1
- Rumor 2
